Carregant...
Inhibiting DosRST as a new approach to tuberculosis therapy
Progress against tuberculosis (TB) requires faster-acting drugs. Mycobacterium tuberculosis (Mtb) is the leading cause of death by an infectious disease and its treatment is challenging and lengthy. Mtb is remarkably successful, in part, due to its ability to become dormant in response to host immun...
Guardat en:
| Publicat a: | Future Med Chem |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Newlands Press Ltd
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7607383/ https://ncbi.nlm.nih.gov/pubmed/32053005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4155/fmc-2019-0263 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|